AbbVie Commits $100M to Morphic in Fibrosis Drug R&D Alliance

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 18, 2018 at 11:42 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via AbbVie is positioning itself to add fibrosis drugs to its pipeline through a new research and development partnership with startup Morphic Therapeutics.

    Under the agreement, AbbVie (NYSE: ABBV) will pay Morphic $100 million up front for exclusive options to license the Waltham, MA, company’s fibrosis drugs. Morphic will be responsible for preclinical research and development.

    article source